These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 24899687

  • 1. Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis.
    Guan B, Rahmanto YS, Wu RC, Wang Y, Wang Z, Wang TL, Shih IeM.
    J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24899687
    [Abstract] [Full Text] [Related]

  • 2. Arid1a inactivation in an Apc- and Pten-defective mouse ovarian cancer model enhances epithelial differentiation and prolongs survival.
    Zhai Y, Kuick R, Tipton C, Wu R, Sessine M, Wang Z, Baker SJ, Fearon ER, Cho KR.
    J Pathol; 2016 Jan; 238(1):21-30. PubMed ID: 26279473
    [Abstract] [Full Text] [Related]

  • 3. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma.
    Guan B, Mao TL, Panuganti PK, Kuhn E, Kurman RJ, Maeda D, Chen E, Jeng YM, Wang TL, Shih IeM.
    Am J Surg Pathol; 2011 May; 35(5):625-32. PubMed ID: 21412130
    [Abstract] [Full Text] [Related]

  • 4. ARID1A mutations in endometriosis-associated ovarian carcinomas.
    Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih IeM, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG.
    N Engl J Med; 2010 Oct 14; 363(16):1532-43. PubMed ID: 20942669
    [Abstract] [Full Text] [Related]

  • 5. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
    Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS.
    BMC Cancer; 2014 Feb 22; 14():120. PubMed ID: 24559118
    [Abstract] [Full Text] [Related]

  • 6. Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A.
    Wu CH, Mao TL, Vang R, Ayhan A, Wang TL, Kurman RJ, Shih IeM.
    Int J Gynecol Pathol; 2012 Jul 22; 31(4):297-303. PubMed ID: 22653341
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma.
    Ayhan A, Mao TL, Seckin T, Wu CH, Guan B, Ogawa H, Futagami M, Mizukami H, Yokoyama Y, Kurman RJ, Shih IeM.
    Int J Gynecol Cancer; 2012 Oct 22; 22(8):1310-5. PubMed ID: 22976498
    [Abstract] [Full Text] [Related]

  • 9. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
    Obata K, Morland SJ, Watson RH, Hitchcock A, Chenevix-Trench G, Thomas EJ, Campbell IG.
    Cancer Res; 1998 May 15; 58(10):2095-7. PubMed ID: 9605750
    [Abstract] [Full Text] [Related]

  • 10. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
    Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O.
    Mod Pathol; 2012 Apr 15; 25(4):615-24. PubMed ID: 22157930
    [Abstract] [Full Text] [Related]

  • 11. Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming.
    Suryo Rahmanto Y, Shen W, Shi X, Chen X, Yu Y, Yu ZC, Miyamoto T, Lee MH, Singh V, Asaka R, Shimberg G, Vitolo MI, Martin SS, Wirtz D, Drapkin R, Xuan J, Wang TL, Shih IM.
    Nat Commun; 2020 Jun 01; 11(1):2717. PubMed ID: 32483112
    [Abstract] [Full Text] [Related]

  • 12. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.
    McConechy MK, Ding J, Senz J, Yang W, Melnyk N, Tone AA, Prentice LM, Wiegand KC, McAlpine JN, Shah SP, Lee CH, Goodfellow PJ, Gilks CB, Huntsman DG.
    Mod Pathol; 2014 Jan 01; 27(1):128-34. PubMed ID: 23765252
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
    Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, Kubo T, Noguchi M.
    Cancer Res; 2000 Dec 15; 60(24):7052-6. PubMed ID: 11156411
    [Abstract] [Full Text] [Related]

  • 17. Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma.
    Su YF, Tsai EM, Chen CC, Wu CC, Er TK.
    Clin Chim Acta; 2019 Jul 15; 494():1-7. PubMed ID: 30851247
    [Abstract] [Full Text] [Related]

  • 18. Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma.
    Mao TL, Ardighieri L, Ayhan A, Kuo KT, Wu CH, Wang TL, Shih IeM.
    Am J Surg Pathol; 2013 Sep 15; 37(9):1342-8. PubMed ID: 24076775
    [Abstract] [Full Text] [Related]

  • 19. Identification of novel mutations of ovarian cancer-related genes from RNA-sequencing data for Japanese epithelial ovarian cancer patients.
    Nagasawa S, Ikeda K, Horie-Inoue K, Sato S, Takeda S, Hasegawa K, Inoue S.
    Endocr J; 2020 Feb 28; 67(2):219-229. PubMed ID: 31748433
    [Abstract] [Full Text] [Related]

  • 20. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.
    Heinze K, Nazeran TM, Lee S, Krämer P, Cairns ES, Chiu DS, Leung SC, Kang EY, Meagher NS, Kennedy CJ, Boros J, Kommoss F, Vollert HW, Heitz F, du Bois A, Harter P, Grube M, Kraemer B, Staebler A, Kommoss FK, Heublein S, Sinn HP, Singh N, Laslavic A, Elishaev E, Olawaiye A, Moysich K, Modugno F, Sharma R, Brand AH, Harnett PR, DeFazio A, Fortner RT, Lubinski J, Lener M, Tołoczko-Grabarek A, Cybulski C, Gronwald H, Gronwald J, Coulson P, El-Bahrawy MA, Jones ME, Schoemaker MJ, Swerdlow AJ, Gorringe KL, Campbell I, Cook L, Gayther SA, Carney ME, Shvetsov YB, Hernandez BY, Wilkens LR, Goodman MT, Mateoiu C, Linder A, Sundfeldt K, Kelemen LE, Gentry-Maharaj A, Widschwendter M, Menon U, Bolton KL, Alsop J, Shah M, Jimenez-Linan M, Pharoah PD, Brenton JD, Cushing-Haugen KL, Harris HR, Doherty JA, Gilks B, Ghatage P, Huntsman DG, Nelson GS, Tinker AV, Lee CH, Goode EL, Nelson BH, Ramus SJ, Kommoss S, Talhouk A, Köbel M, Anglesio MS.
    J Pathol; 2022 Apr 28; 256(4):388-401. PubMed ID: 34897700
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.